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Abstract 
Diseases caused by obstruction or rupture of vulnerable plaques in the arterial walls such as 
cardiovascular infarction or stroke are the leading cause of death in the world. In the present work, we 
developed human serum albumin nanoparticles loaded by physisorption with zinc phthalocyanine, TT1, 
mainly used for industrial application as near-infrared photosensitizer and compared these to HSA NPs 
loaded with the well-known silicone phthalocyanine (Pc4). The use of NIR light allows for better tissue 
penetration, while the use of nanoparticles permits high local concentrations. The particles were 
characterized and tested for toxicity and stability as well as for their potential use as a contrast agent 
and NIR photosensitizer for photodynamic therapy in cardiovascular disease. We focused on the 
distribution of the nanoparticles in RAW264.7 macrophage cells and atherosclerotic mice. The 
nanoparticles had an average size of 120 nm according to dynamic light scattering, good loading 
capacity for zinc phthalocyanine, and satisfying stability in 50% (v/v) fetal bovine serum for 8 hours 
and in an aqueous environment at 4°C for 4–6 weeks. Under light irradiation we found a high production 
of singlet oxygen and the products showed no dark toxicity in vitro with macrophages (the target cells 
in vulnerable plaques), but at a low µg/mL nanoparticle concentration killed efficiently the 
macrophages upon LED illumination. Injection of the contrast agent in atherosclerotic mice led to a 
visible fluorescence signal of zinc phthalocyanine in the atherosclerotic plaque at 30 minutes and in the 
lungs with a fast clearance of the nanoparticles. Zinc phthalocyanine loaded human serum albumin 
nanoparticles present an interesting candidate for the visualization and potentially photodynamic 
treatment of macrophages in atherosclerotic plaques. 
Keywords: Photodynamic therapy, cardiovascular disease, phthalocyanine, albumin nanoparticles
Rationale and Purpose 
Diagnostic tools able to identify vulnerable 
plaques which are more prone to burst than the 
thicker partially occluding stable plaques in 
arteriosclerosis are very limited. Vulnerable 
plaques are prone to rupture easier due to a thin 
fibrotic flap and macrophages digesting the 
fibrotic material by the release of 
metalloproteinases. A contrast agent which 
allows to visualize preferentially those plaques 
and reduce the high content of macrophages 
would be a new therapeutic option which can 
prevent stroke or cardiac infarction. 
Photodynamic therapy (PDT) offers the 
possibility of a very localized treatment of cells 
which have up taken the drugs and only after 
activation by invasive light which significantly 
reduces side-effects. Recently it was shown that 
PDT had a beneficial effect even for the 
treatment of cardiovascular disease (CVD). 
Albumin nanoparticle delivery for the NIR 
photosensitizer was chosen as because of the 
good biocompatibility of albumin, expected 
long half-life time in blood, low expected 
protein corona, and good loading capacity of 
albumin for different types of molecules in its 
native form. A NIR dye will allow the 
activation by light even in deeper tissue layers. 
Introduction 
According to WHO (2017), cardiovascular 
disease (CVD) along with stroke are the major 
cause of death (17.9 million per year due to 
CVD presenting 1/3 of the global death) and 
disability across the globe for non-
communicable diseases with a prevision of an 
even higher death toll in the future.1,2 
Myocardial infarction and stroke are induced 
by an embolus which forms upon rupture of 
vulnerable atherosclerotic plaques, leading to 
occlusion and ischemia.3–5 Atherosclerosis is a 
slow progressing pathophysiological condition 
in which lipids and blood-borne material 
deposits in the form of plaques within the 
arterial wall.6 The plaque formation is a 
complex process involving multiple steps such 
as the formation and “bursting” of macrophage 
foam cells (necrosis), extracellular lipid 
accumulation, loss of structural integrity of 
smooth muscle cells, solid cholesterol 
deposition (needle-like crystals), calcification, 
and hematoma formation and transformation 
causing chronic inflammation, 
neovascularization, fibrotic flap disruption, and 
fibromuscular tissue formation from 
thrombus.7,8 Moreover, studies support the 
important role of cellular processes including 
mechano-transduction and endothelial cells 
inflammation, the invasion of macrophages, 
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and a phenotypic switching of smooth muscle 
cells in the lesions.9 Given the manifold events 
taking place in plaque formation, one can 
distinguish 2 types of plaques: (i) those 
stabilized by calcification and (ii) those that are 
vulnerable that have been destabilized by a 
thinning of the fibrotic cap due to matrix 
metalloproteinase digest and macrophage.5 
The “gold standard” for diagnostics of CVD 
is angiography. However, one of the limitations 
of the technique is that it visualizes significant 
occlusions formed mainly by stable plaques. 
Another diagnostic tool is the more invasive 
cardiac catheterization, which gives more 
detailed information and allows for immediate 
treatment.10,11 While techniques do exist to 
visualize plaques in general, methods to 
distinguish vulnerable plaques responsible for 
70% of the deadly infarctions from stable, 
calcified plaques are very limited. Therefore, a 
technology able to identify these plaques in a 
non-invasive manner and at the same time 
allow for treatment would be preferred for 
management of CVD.  
PDT is a non-invasive local treatment known 
as a palliative treatment for non-invasive skin 
conditions such as basal cell carcinoma and 
other superficial cancers.12 Recently, it was 
studied as a promising treatment option for 
application in other medical problems such as 
periodontitis.13,14 or in gynecology.15 After the 
application of a non-toxic photosensitizer, the 
treated area (dye accumulates in tumor due to 
enhanced permeation and retention effect) is 
irradiated with non-toxic preferentially near-
infrared (NIR) light (has a better and deeper 
tissue penetration12,16), which activates the 
photosensitizer. The photosensitizer produces 
singlet oxygen which damages or kills the 
target cells selectively. A second mechanism of 
cell killing is the production of reactive oxygen 
species by the exposure to the singlet oxygen. 
This treatment allows for the eradication of the 
malignant cells without severe side-effects for 
the body.17 Increasing evidence indicates the 
importance of nanoparticulated photosensitizer 
and PDT for diagnostics and treatment of 
CVD.18–21 It was shown that PDT for CVD, 
named photoangioplasty in clinical trials, can 
significantly reduce the plaque size.22.23 The 
drug diffuses into the plaque in a process which 
is similar to enhanced permeation, and retention 
observed in the tumor due to an impairment in 
the integrity of the vessel wall either of the 
lumen from affected vessels or 
neovascularization of the vasa vasorum.24 
Frequently used molecules such as NIR-PDT 
photosensitizers are phthalocyanines (Pc) 
which have low, dark toxicity but high 
phototoxicity due to a high yield of singlet 
oxygen production, strong absorption in the 
red-NIR region, and fast clearance from the 
body.25–29 For example, silicon-based 
phthalocyanine (Pc4) is a known second-
generation photosensitizer, generating singlet 
oxygen upon photoirradiation with an 
absorption in the far red at 675 nm and has been 
used for treating cancer and other diseases.30–34 
Given the additional fluorescence properties of 
photosensitizers, they can be used both as 
therapeutics and as diagnostics, sometimes 
called “theranostics.” One of the drawbacks is 
that the hydrophobic sensitizer mainly 
accumulates in the cell membrane therefore 
killing the cell by necrosis rather than by 
apoptosis.33 Necrosis leads to a local 
inflammation by the release of cytosolic 
content. Here, a nanoparticle delivery system 
can increase on one hand the intracellular 
concentration of hydrophobic drugs and on the 
other hand, shift the sensitizer entry to an 
endocytic uptake and hence apoptotic cell 
death. Nanoparticulated formulation allows 
changing the biodistribution of the 
photosensitizer and seems to improve the 
efficacy of phthalocyanine photosensitizers in 
PDT.35 Recently, different nanoparticle 
delivery systems for PDT in CVD were tested 
such as micellar preparations36 or 
dendrimers.37,38 While the micellar preparations 
were not stable enough to confirm the good in 
vitro data also in vivo experiments36 the 
dendrimers were studied only in vitro in a very 
artificial system.37 
Experimental 
The present work describes the development 
and characterization of NIR photosensitizer 
(silicon Pc [Pc4], zinc-based Pc [TT1]) loaded 
human serum albumin nanoparticles (HSA-NP) 
and their potential applicability in PDT. The 
best performing particles were tested for 
biological performance including macrophage 
killing efficacy after illumination, immune 
safety (in vivo in a pig model, and in vitro by 
complement activation assays on blood) as well 
as its accumulation in plaques in an 
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atherosclerotic mouse model as well as off-
target organs. 
Materials and Methods 
HSA, non-substituted zinc phthalocyanine 
(ZnPc), 1,3-diphenylisobenzofuran (DPBF), 
Eosin Y, 9,10-anthracenediyl-bis(methylene)-
dimalonic acid (ADMA) and dimethyl 
sulfoxide (DMSO) were purchased from 
Sigma-Aldrich. Ethanol was purchased from 
VWR Chemicals, Prolabo (Milan, Italy). All 
chemicals and solvents were analytical grade 
and used without further purification.  
Figure 1. Chemical structure of TT1 (left) and Pc4 (right).
Preparation of phthalocyanines 
The synthesis of TT1, a photosensitizer 
originally used for solar cells, was carried as 
reported in the literature.39,40 In brief, the 
synthesis initiated with a statistical 
condensation of 4-tert-butylphthalonitrile and 
4-hydroxymethylphthalonitrile (in a 4:1 ratio), 
in the presence of zinc acetate as metal salt and 
refluxing dimethylaminoethanol (DMAE) as a 
solvent. From the obtained hydroxymethyl-Pc, 
2 successive oxidation steps with pyridine-SO3 
complex and NaClO2/H3NO3S lead to the final 
product TT1 (Figure 1 left). A detailed 
physicochemical characterization of TT1 can 
be found in Cid et al.35 
The synthesis of Pc4 (Figure 1 right) was 
carried out adapting procedures from 
literature.41,42 In particular, the reaction 
between silicon phthalocyanine (SiPc) 
dihydroxide (SiPc(OH)2) and 3‐
(methoxydimethylsilyl)‐N,N‐dimethylpropan‐
1‐amine in distilling pyridine yields a SiPc 
derivative with 2 di-methylaminopropylsiloxy 
axial substituents. The selective displacement 
of one of these substituents with trichloro-
acetate and the subsequent substitution of the 
latter with an OH ligand allows obtaining Pc4 
in an overall yield of 70%.  
Synthesis of Pc-loaded HSA-NPs 
Empty HSA nanoparticles were prepared by a 
modified desolvation technique first described 
by Langer et al.43 For this, 8.0 mL absolute 
ethanol was added at a rate of 1mL/min under 
continuous stirring (500 rpm) at room 
temperature to 200 mg HSA dissolved in 2.0 
mL of 10 mM NaCl solution (pH-8.10). Then 
0.8% (v/v) glutaraldehyde in water (5.88 µL) 
was added to induce particle cross-linking and 
the suspension was stirred for 24 hours at room 
temperature. NPs were collected and washed by 
centrifugation (16595 × g) for 15 minutes at 
20°C and resuspension in ethanol followed by 
sonication for 15 minutes (repeated twice). 
Finally, the supernatant was removed, and the 
NPs were dried in a desiccator for 48 hours. The 
HSA-NPs were stored as a dry powder at RT 
upon use. In order to study the influence of 
different desolvation agents and volumes as 
well as the speed of desolvation addition on the 
particle size and dispersity index, smaller test 
batches were prepared with ¼ of the described 
volumes (Table S1).  
For the preparation of HSA-Pc4 and HSA-
TT1 NPs, 100 mg of HSA was dissolved in 2 
mL of 10 mM NaCl (pH=8.10). Predetermined 
volumes of the stock solution of the respective 
dyes in DMSO were added to the HSA solution 
and the mixtures were incubated in dark for 2 
hours with occasional vortex. The ratio of the 
dyes to the HSA varied from 1:10 to 1:20 for 
various formulations (10, 20, 40, 80, 120, 160 
µL). Cross-linking and NP purification 
followed the same procedure described for 
empty HSA-NPs. Washing steps were repeated 
until a colorless supernatant was obtained. The 
supernatants were pooled in order to determine 
the dye entrapment.  
N
N
N
N
N
N
N
N
Si
O
OH
Si
N
C39H35N9O2Si2
Exact Mass: 717,25
Mol. Wt.: 717,93
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Encapsulation efficiency 
Powdered NPs were dissolved in phosphate-
buffered saline (PBS) to a concentration of 1 
mg/mL. The entrapment efficiency and yield 
were determined with UV-Vis spectroscopy 
using Ultraspec 2100 pro (Amersham 
Biosciences, US). The dry weight of the 
nanoparticles was measured. The yield of the 
nanoparticle synthesis was calculated44 by the 
formula: %	 NP	 Yield	 =	 (Weight	 of	 NPs	 obtained/	[weight	 of	 dye+weight	 of	 HSA	 used	 for	 NPs	synthesis])	×	100	
The protein content of the obtained NPs was 
calculated using Bradford assay according to 
the protocol provided by the manufacturer. 
Briefly, 10 µL of HSA-NPs (1 mg/mL) were 
added into 990 µL of diluted Bradford reagent 
and incubated at RT for 20 minutes. The 
absorbance was measured at 595 nm and the 
HSA concentration of the NPs was calculated 
by means of an HSA standard curve. 
During the synthesis of the nanoparticles, the 
number of dyes in the supernatant after each 
step of centrifugation was quantified to 
calculate the entrapment efficiency of the 
respective dyes in the nanoparticles. A standard 
curve was plotted before using standard 
concentrations of dye dissolved in DMSO. The 
spectrophotometric quantification was done by 
measuring the absorbance at 672 and 680 nm 
for Pc4 and TT1, respectively. The percentage 
of encapsulated dye was calculated using:  %Entrapment=	(1-	[Free	dye	concentration/	Initial	dye	concentration])	×	100		
Physicochemical characterization 
Dynamic light scattering analysis and zeta 
potential 
Immediately before use, the Pc-loaded HSA-
NPs were dissolved in water to concentrations 
of 6.96 µM Pc4 and 7.5 nM HSA and 6.37 µM 
TT1 and 7.5 nM HSA respectively. The 
diameter, size distribution. and electrophoretic 
mobility of HSA, HSA-Pc4 and HSA-TT1 NPs 
were measured by (DLS) using Nano ZS 
(Malvern, UK). In order to use the 
recommended attenuator settings of 7-9, the 
NPs were diluted for the DLS measurement. 
The zeta potential was obtained by a further 10-
fold dilution in Milli-Q grade water of the DLS 
sample to reduce the back scattering since the 
measurement was not performed at 173° NIBS 
as for DLS. 
Nanoparticle tracking analysis  
The size and concentration of HSA-TT1 NPs 
were analyzed by nanoparticle tracking analysis 
(NTA) using an LM-10 (NanoSight, Malvern 
Instruments, Malvern, UK). The particles for 
NTA had a ratio of 1:10 (dye:HSA). 
Measurements on appropriately diluted NPs in 
PBS were performed in triplicates of 60-second 
video captures with camera level 11 and 
detection threshold 5. The data were analyzed 
using software version 3.0. 
UV-Vis  
The fluorescence emission spectra of the Pc-
loaded NPs were measured by UV-Vis using an 
LS 55 Luminescence spectrofluorometer 
(Perkin Elmer, USA). For this measurement 
NPs were dissolved in water and measured at 
an excitation wavelength of 670 nm for TT1-
HSA and λex=680 nm for Pc4-HSA NPs 
respectively. 
Negative stain high-resolution transmission 
electron microscopy and energy dispersive 
spectroscopy  
10 μL of the samples (1 mg/mL in distilled 
water) were deposited on a 300-mesh copper 
grid coated with carbon (Electron Microscopy 
Sciences, USA). After 1 minute, the excess 
sample was removed and a drop of 2% (w/v) 
ammonium molybdate was placed on the grids 
to negative stain the HSA-NPs. The excess 
negative stain was removed, and the grids were 
air-dried. The morphology of the nanoparticles 
was observed using a transmission electron 
microscope (TEM) JEM-2100 HRTEM (JEOL, 
Japan) along with energy dispersive 
spectroscopy (EDS) detector in bright field 
mode under an operating voltage of 200 kV. 
The elementary analysis by EDS was 
performed to confirm the presence of Zn and Si 
in the phthalocyanine-loaded HSA-NPs.  
Attenuated total internal reflection - Fourier 
Transform Infrared Spectroscopy (ATR-FT-IR) 
200 µL of the Pc dye-loaded HSA-NPs were 
added on the surface of zinc selenide (ZnSe) 
ATR crystal as described previously 45 to 
obtain a uniform film on the crystal. The 
experiments were performed in Nexus-870 
FTIR spectrometer (Thermo Nicolet 
Corporation, USA) by scanning in the infrared 
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region of 4000 – 800 cm-1. The data obtained 
was analyzed using the OMNIC software 
(version 6.0 A) bundled with the instrument. 
Background spectra measured with the blank 
ZnSe crystal were subtracted from the 
individual spectrum. Fourier Transform 
Infrared Spectroscopy was employed to study 
possible interactions and bonding patterns 
between the Pc4 dye and HSA.  
Determination of Singlet Oxygen Quantum 
Yield 
As some of the photosensitizers showed 
significant quenching in an aqueous 
environment it was necessary to determine the 
quantum yield both in water and DMSO. 
Yield in DMSO 
Singlet oxygen quantum yields (ΦΔ) of Pc4 
and TT1 dye, HSA, HSA-Pc4 and HSA-TT1 
NPs were measured in DMSO, following a 
procedure reported by Wohrle et al.46 based on 
the photo-induced decomposition of the 
chemical trap 1,3-diphenylisobenzofuran 
(DPBF). Non-substituted ZnPc was used as 
reference compound (ΦΔ(DMSO) = 0.67).47 A 
2 mL stock solution of DPBF (with an 
absorbance of ca. 1) in DMSO was taken in a 1 
× 1 cm quartz optical cell and kept for 1 minute. 
A concentrated stock solution of ZnPc in 
DMSO was then added, in a defined amount to 
reach an absorbance of the final solution in the 
Q-band maximum of about 0.1. The solution 
was stirred and irradiated for defined time 
intervals using a halogen lamp of 300 W. The 
incident light was filtered through a water filter 
and an orange HOYA G filter to remove heat 
and light under 530 nm, respectively. The 
decrease of DPBF concentration in DMSO 
solution with irradiation time was monitored at 
417 nm in a UV-Vis spectrophotometer. The 
data was plotted for further calculations.  
Yield in water 
The singlet oxygen quantum yields (ΦΔ) of 
HSA, HSA-Pc4 and HSA-TT1 NPs were 
measured in H2O as reported earlier based on 
the photo-induced decomposition of the 
chemical trap α,α`-(anthracene-9,10-diyl)-
dimethyl-malonic acid (ADMA). Eosin Y was 
used as reference compound (ΦΔ(H2O)=0.60)65 
Experimental measurements were carried out as 
mentioned before, with a few modifications. 
Incident light was filtered through a water filter 
and an MS filter to remove heat and light under 
455 nm, respectively. Decrease of ADMA 
concentration in H2O solution with irradiation 
time was monitored at 380 nm in a UV Vis 
spectrophotometer. Data obtained were plotted 
and calculations were done in order to get the 
singlet oxygen quantum yield. 
Stability study of HSA-Pc4 and HSA-TT1 NPs 
Serum stability  
A stock solution was prepared by suspending 
the NPs with and without photosensitizer in 
deionized water to a concentration of 1 mg 
mL−1. Next, nanoparticles (Pc4-HSA and TT1-
HSA) were added to 50% (v/v) FBS or to a 
physiological saline solution on a thermoshaker 
for up to 24 hours at room temperature. An 
aliquot of the NPs was collected at 
predetermined time points of 2, 4, 8, and 24 
hours to determine the amount of released dye 
and NP size. NPs were centrifuged at 12500 
rpm (16595 × g) for 15 minutes at 20ºC and the 
supernatant was collected and analyzed with a 
spectrophotometer to calculate the release dye 
percentage. 
Stability of NP solution 
The NPs as prepared were suspended in 
deionized water at a concentration of 1 mg/mL 
to form a stock solution and stored at 4ºC for up 
to 6 weeks. Every week the NP size distribution 
and zeta potential were calculated using DLS. 
In order to determine the amount of released 
dye, the NPs were centrifuged for 15 minutes at 
16595 × g and the supernatant was analyzed in 
UV-Vis spectrophotometer to determine the 
amount of released dye.  
In vitro experiments 
Murine macrophages RAW264.7 were grown 
in Dulbecco’s modified Eagle’s Medium 
(Gibco) supplemented with 10% heat 
inactivated FBS, L-glutamine (2 mM), 1% non-
essential amino acids, 1% sodium pyruvate, 
penicillin (100 U mL−1), streptomycin (100 µg 
mL−1). Cultures were incubated at 37°C, 5% 
CO2 and passaged regularly when reaching 70–
80% confluence.  
HSA-NPs with and without photosensitizer 
dye were sonicated (Bandelin, Sonorex) for 15 
minutes prior to cell incubation. The complete 
absence of free dye from the loaded NPs was 
tested according to the protocol reported by 
Andreozzi et al.48 Cell membranes were stained 
with Cell MaskTM Green (Life Technologies, 
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Monza, Italy), following the manufacturer’s 
instructions. Cellular uptake and internalization 
of labeled NPs was visualized by using an 
inverted confocal laser scanning microscope 
(Leica TCS SP5) equipped with 488 and 633 
nm laser lines.  
In vitro cell killing and dark toxicity  
Murine macrophages RAW264.7 were grown 
in Dulbecco’s modified Eagle’s Medium 
(Gibco) supplemented with 10% heat 
inactivated FBS, L-glutamine (2 mM), 1% non-
essential amino acids, 1% sodium pyruvate, 
penicillin (100 U mL−1), streptomycin (100 µg 
mL−1). Cultures were incubated at 37°C, 5% 
CO2 and passaged regularly when reaching 70–
80% confluence.  
HSA-NPs with and without photosensitizer 
dye were sonicated (Bandelin, Sonorex) for 15 
minutes prior to cell incubation. The complete 
absence of free dye from the loaded NPs was 
tested according to the protocol reported by 
Andreozzi et al.44 
The cell-killing efficacy as well as the dark 
toxicity of HSA-NPs was analyzed on 
RAW264.7 cells using MTS assay (Promega, 
Milan, Italy). In this assay, cells seeded into a 
96-well plate. After 24 hours, HSA-NPs were 
added to the cells in escalating doses, and the 
cells were incubated for another 24 hours. The 
cells were illuminated with a custom-made 
LED device emitting light at 670 nm 
wavelength for 10 minutes, with LED light 
intensity of 3.04 mW/cm2. Twenty-four hours 
later, MTS reagent was added to the cells for 1 
hour and the resulting signal was analyzed by 
spectrophotometry (Multiskan Ascent, MTX 
Labsystems, Florida, USA). Cells without 
nanoparticles were used as a control, as well as 
solutions containing only the nanoparticles but 
no cells. The dark toxicity of the compounds 
was analyzed without LED light illumination. 
In vitro complement activation assays  
Details for human serum preparation, 
characterization and functional assessment of 
complement pathways were in accordance with 
our previous studies.49,50 To measure 
complement activation in vitro, we determined 
the NP-induced rise of human serum 
complement products C5a and sC5b-9 using the 
respective ELISA kits (Quidel, San Diego, CA, 
USA) according to the manufacturer’s 
protocols as described previously.45,46 Briefly, 
complement activation was initiated by adding 
the required quantity of TT1 loaded HSA-NPs 
to undiluted serum in Eppendorf tubes in a 
shaking water bath at 37°C for 30 minutes, 
unless stated otherwise. Reactions were 
terminated by quickly cooling samples on ice 
and adding 25 mM ethylenediaminetetraacetic 
acid (EDTA). After centrifugation, the 
supernatant was used for the determination and 
quantification of complement activation 
products C5a and sC5b-9. Control serum 
incubation contained PBS (the same volume as 
the NP samples) to assess background levels, 
and zymosan (1 mg/mL) was used as a positive 
control for monitoring complement activation 
throughout. Sera from 3 individuals were tested 
separately and each incubation was performed 
in triplicates.  
Nanoparticle administration in vivo 
Pig model 
Three young male pigs of 21, 21, and 24 kg 
were used for in vivo administration of TT1-
HSA-NPs. The animals were purchased from 
approved experimental animal vendors. They 
remained in quarantine for 5 days prior to the 
experiments. The closed chest in vivo pig 
experiment was performed on anesthetized 
pigs. Animals were sedated by intramuscular 
injection of Calypsol/Xilazine (2–4/1.5–2 mL, 
based on body weight) injections in the stalls to 
avoid stress, and were transported sedated to the 
operating room. The anesthesia was maintained 
using isoflurane inhalation narcosis (2–3%) 
with oxygen. The pigs were instrumented with 
Swan-Ganz catheter (Ref. No.: AI-07124, 5 Fr. 
110 cm, ARROW INTERNAT. INC.), 
introduced into the pulmonary artery through 
the right external jugular vein → right atrium 
→ right ventricle. The pulmonary arterial 
pressure (PAP) was monitored using a pressure 
transducer, and a second pressure transducer 
was connected to the cannula in the left femoral 
artery to record the systemic arterial pressure 
(SAP). The left femoral vein was cannulated for 
blood sampling (for blood cell counts and for 
TxB2 measurements) and the left external 
jugular vein was cannulated for fluid supply 
and administration of control and test materials. 
All incision areas were shaved and disinfected 
by a liberal application of povidone-iodine 10% 
and closed by suture after fixation of cannulas. 
PAP, SAP, heart rate (HR), and 
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electrocardiography were continuously 
monitored and recorded by ADInstruments 
LabChart Pro v8 model and software. Other 
details of surgery, instrumentation and 
hemodynamic analysis were described in the 
original studies.51,52 
Testing procedure 
Baseline blood samples were taken, and the 
physiological parameters were recorded for 15 
minutes before the first injection of the test 
material. Initially pig 1 and pig 2 were injected 
with previously prepared TT1-HSA-NPs (2.5 
mg in 20 mL (=0.125 mg NP/mL for 0.1 mg/kg) 
and 25 mg in 20 mL (1.25 mg NP/mL for 1 
mg/kg). 
For experiments with the highly concentrated 
NP solutions, the sample was prepared fresh 
from lyophilized dry powder by dilution in 
saline to the final concentration of 300 mg in 20 
mL (=15 mg NP/mL) for an injection of 10 mg 
NPs/kg weight per pig (pig 3). From this stock 
solution, the concentrations of 1 mg/kg and 0.1 
mg/kg pig were prepared. The respective 
suspensions were bolus injected into the left 
external jugular vein. Boluses were flushed into 
the circulation with an additional 5 mL of saline 
solution. The complete test involved 
quantitation of the cardiopulmonary, 
hemodynamic, skin, hematologic and blood 
chemical changes.  
Atherosclerotic mouse model  
For biodistribution study, 11-month-old male 
LDLR-/-/ApoB100/100 - mice were used at 
different time points (30 minutes, 3 hours, and 
24 hours). Mice were fed on Western type diet 
TD 88137 Harlan Teklad, 42% calories from fat 
and 0,15% from cholesterol, Envigo) diet for 7 
months. Diet and water were provided ad 
libitum. The NPs were dissolved from dry 
powder and TT1-HSA-NPs were injected via 
tail vein to a final concentration of 1 mg NPs/kg 
weight per mouse. All animal procedures were 
approved by The Animal Experiment Board in 
Finland and carried out in accordance with the 
guidelines of the Experimental Animal 
Committee of the University of Eastern 
Finland.  
Results and Discussion 
Preparation and characterization of the Pc-
loaded HSA-NPs 
Experiments to optimize the preparation 
conditions for the nanoparticles were 
performed by varying the desolvation solvent 
and the speed by which the solvent/mixture was 
added to the HSA solution (Table S1). We 
observed that the composition of the 
desolvation agents as the added volume has 
some limited influence on the particle size as 
well as on the polydispersity index (Table S1). 
Summarizing the results, we determined that 
the smallest HSA-NPs with the lowest 
polydispersity index (PDI) of particles were 
prepared with 6:2=acetone/water. Additionally, 
we found that slow desolvant addition in the 
presence of the photosensitizer TT1 led to 2 
peaks in all preparations except for using pure 
ethanol (data not shown). Therefore, we 
continued the preparation with ethanol as a 
desolvation agent because of its lower toxicity. 
The Pc (TT1, Pc4) loaded HSA-NPs were 
prepared with different photosensitizer 
concentrations and the resulting nanoparticles 
were characterized for their size (DLS), surface 
charge (zeta potential), entrapment efficiency, 
and singlet oxygen production (Table S2). The 
singlet oxygen quantum yield was determined 
in order to evaluate a potential efficacy for 
PDT. For the free Pc4 and TT1 dyes in DMSO, 
the yield was calculated to be 0.227 and 0.353 
respectively, while for the HSA NP the yield 
was 0.014 for Pc4 and 0.016 for TT1 in water. 
The significant lower singlet oxygen yield of Pc 
bound to the HSA NP was explained due to 
quenching of the photosensitizer in the 
presence of water as compared to DMSO and 
the interaction of the produced singlet oxygen 
with the HSA. (Table S2). 
Fluorescence absorbance and fluorescence 
emission intensity detected in the UV-Vis 
spectra confirmed the increase in loading of the 
HSA-NPs with Pc4 or TT1 with the increasing 
amount of added photosensitizer (Figure S1). 
As it demonstrated in Figure S1, Pc4 gave a 
visible absorbance at 635 nm for 
concentrations >3.48 µM Pc4 (Figure S1A), 
while TT1 already showed an absorbance 
signal at 1.58 µM TT1 (Figure S1B). 
Fluorescence emission spectra confirmed the 
absorbance data as expected. 
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Figure 2. Representative transmission electron microscopy images (left) and energy-dispersive x-ray spectroscopy (EDS) 
(right) spectra of Pc4-HSA-NPs (Upper panel) and TT1-HSA-NPs (Lower panel) are depicted. The EDS spectra confirmed 
the presence of the Pc4 in the nanoparticles. 
In order to confirm the localization of the 
photosensitizers within the NPs we performed 
TEM with energy-dispersive x-ray 
spectroscopy (EDS) analysis. TEM images in 
Figure 2 show spherical HSA-NPs for which 
the EDS analysis confirmed a Si signal of Pc4 
in the area of the NPs (upper panel) and Zn 
indicative for TT1 loaded on the HSA-NPs 
(lower panel). TEM images show that the NPs 
with the highest content of Pc4 or TT1 give 
single well-defined spheres with a smooth 
surface and a diameter of 200–300 nm. 
In addition to TEM, which shows the size of 
the dehydrated particles (Figure 2), the 
hydrodynamic diameter was determined by 
dynamic light scattering (Figure 3 and Tables 
S1–S4). In DLS, the hydrodynamic diameter 
for the TT1 loaded HSA-NPs was around 203 
nm with a PDI of 0.15.  
Next, we tested the stability of the dye-loaded 
HSA-NPs in different conditions (saline at 
37°C 50% FBS at 37°C (condition in blood), 
H2O at 4°C (storage condition)). In order to 
determine the dye leakage in serum conditions, 
which plays a crucial role in predicting the in 
vivo behavior, we incubated Pc-loaded HSA-
NPs for 24 hours at 37°C in high-serum 
concentrations (50%) to mimic the conditions 
in the body (Figure 2B, D). The release profile 
of the Pc-loaded nanoparticles kept in water at 
4°C for up to 6 weeks can be found in Tables 
S3 and S4.  
At a temperature of 37 °C and in the presence 
of 50% (v/v) FBS, the release profile for TT1-
HSA showed a burst release around 3% of TT1 
and then no more release up to 8 hours. (The 
initial burst release may be due to the release of 
molecules loosely attached to the NP surface.) 
The slight increase in the hydrodynamic 
diameter indicates a swelling of the particles 
consistent with an entry of water molecules and 
a loosening of the NP matrix. After 8 hours a 
stronger leakage of TT1 was observed. 
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Figure 3. Time-dependent release of (A) Pc4 or (C) TT1 from HSA-NPs in 50% (v/v) fetal bovine serum (FBS) (blue line) or 
saline at 37ºC (red line). Panels B and D show the change of the hydrodynamic diameter measured in 50% FBS at 37°C for 
human serum albumin nanoparticles loaded with Pc4 (B) and TT1 (D). The lines serve only to guide the eye. 
Pc4-NP leaked continuously but slowly dye 
from the nanoparticles (Figure 3A). For both 
dyes, it was observed that after 24 hours the Pc 
release reached around 25% of the dye content. 
In contrast, the NPs loaded with Pc4 or TT1 
stored in physiological saline solution (0.9% 
NaCl) showed negligible release of the dye, 
even after 24 hours at 37 °C.  
The particles exhibited a satisfying shelf-life, 
(stability and Pc4 release in Milli-Q grade water 
at 4°C) the Pc4-loaded NP solutions showed no 
release of the Pc4 and no significant change in 
the PDI or hydrodynamic diameter for up to 4 
weeks. The NPs (HSA-Pc4 and HSA-TT1) 
were found to be stable in pure water for 6 
weeks at 4 ºC, after which the NPs seem to 
break down (Table S1). The difference in the 
release profiles in FBS indicates that the Pc4 
and the TT1 are bound in different ways to the 
scaffold of cross-linked HSA. This is also 
confirmed by the FTIR measurements (Figure 
4). ATR-FTIR was performed to detect the 
effect of the phthalocyanine dyes within the 
HSA structure and its conformation that play a 
role in the NP stability. HSA-NPs exhibited a 
significant shift in the protein amide I band 
arising from the C=O stretch from 1674 cm−1 
to 1659 cm−1 with respect to HSA in solution, 
which can be explained by the glutaraldehyde-
protein cross-linking during the NP formation. 
Further evidence of conformational changes of 
HSA in the HSA-NPs could be obtained from 
the shift in the stretching vibration of the N-H 
bond from 3301 cm−1 to 3310 cm−1. The 
amide-II band at 1540 cm−1 arising from the C-
N stretching coupled with the N-H bending 
vibration was not shifted but showed a reduced 
intensity. FTIR results indicate structural 
changes arising from intramolecular bonding: a 
phenomenon probably arising from the 
conformational changes of the protein when it 
forms a nanoparticle from its native state. The 
presence of TT1 resulted in further red shift of 
the amide-1 band to 1656 cm−1 but left the 
amide-II band unchanged. 
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Figure 4. ATR-FTIR spectra of (A) Pc4 and (B) TT1-loaded human serum albumin (HSA) nanoparticles (NPs), empty HSA-
NPs, human albumin solution, and the photosensitizer alone. 
Both bands were of slightly reduced 
intensities in comparison to the unloaded HSA-
NPs indicating the minor changes in the protein 
conformation arising from reorganized intra- 
and intermolecular bonding in presence of TT1 
The presence of Pc4 exhibited pronounced 
changes in the intensities of both the amide-II 
bands but did not display any shift in the wave 
numbers for the respective Amide bands. Such 
enhanced alteration in the intensities were 
indicative of significant protein conformational 
changes that could have a role in the 
reorganization of protein secondary structures. 
Nanoparticle uptake and cytotoxicity 
The toxicity of the HSA NP loaded with TT1 
or Pc4 were tested by an MTS test on 
RAW264.7 macrophages as a model for off-
target cells which can accumulate high 
quantities of the NPs by unspecific uptake. 
Figure 4 displays the toxicity of 
photosensitizer loaded NPs tested at different 
concentrations (0–25 ng/µL for TT1 and 0–250 
ng/µL for Pc4). 
 
 
Figure 5. MTS test for cyto- (white bars) and photocytotoxicity induced by singlet oxygen production (black bars) of TT1-
human serum albumin nanoparticles (HSA-NPs) (A) in the concentration range from 0.5 to 25 ng/µL and Pc4-hsa-NP (B) in 
the concentration range from 5 to 250 ng/µL on RAW264.7 macrophages after 24 hours of incubation. The treated cells were 
illuminated with a custom-made LED device for 10 minutes. Non-illuminated cells were used as a control. 
MTS test on RAW264.7 macrophages 
indicated an extremely low toxicity of HSA-
NPs even at higher concentrations (Figure 5, 
white bars). The ability of photosensitizer (Pc4, 
TT1) loaded HSA-NPs to trigger apoptosis by 
light-induced singlet oxygen production was 
studied in macrophages, the intended target 
cells for the PDT treatment.  
RAW264.7 cells were exposed to increasing 
concentration of the NPs and the IC50 value 
was estimated (Figure 5). Cells then were 
illuminated with a custom-made LED device 
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for 10 minutes, with an energy of 3.04 mW/cm2 
(1824 mJ/cm2). Non-illuminated cells were 
used as control for the dark toxicity of the NPs. 
For HSA NP containing TT1, the value was 
17.5 ng/µL (Figure 5A; black bars). HSA NP 
with Pc4 showed cell-killing efficacy with 
IC50-value of 45 ng/µL (Figure 5B; black 
bars). Next, we wanted to investigate the 
cellular uptake and localization of the loaded 
nanoparticles (Pc4-HSA-NPs and TT1-HSA-
NPs). Therefore, we incubated RAW264.7 cells 
with 200 µg/µL NPs and visualized them by 
confocal microscopy at different time points up 
to 24 h (Figure 6 and S1). In Figure 6, the high 
magnification merged confocal fluorescence 
microscopy and transmission image of the focal 
plane of some RAW cells incubated for 24 
hours with 200 µg/mL TT1 HSA-NPs are 
shown. The image shows the cellular uptake 
and localization for TT1 HSA-NPs revealed by 
the first fluorescence signal inside the 
macrophages (RAW264.7 cells) after 2 hours of 
incubation. From the spotty appearance of the 
fluorescence signal (Figure 6, left) and the z 
stack in confocal microscopy (Figure 6 Right) 
at 24 hours incubation, we concluded that the 
nanoparticles are localized in vesicular 
structures such as endosomes.  
 
 
 
 
 
 
 
 
Figure 6. (left) High magnification merged confocal fluorescence microscopy and transmission image of the focal plane of 
RAW cells (right) z stack by confocal microscopy of a macrophage incubated for 24 hours with 200 µg/mL TT1 HSA 
nanoparticles. The blue fluorescence is due to Hoechts, a nuclear stain, the pink color indicates the red fluorescence of the 
membrane stain, CellMask. The red signal is due to the fluorescence signal of TT1. The micrograph confirms the 
morphological appearance of the macrophage.  
Both the distribution of the NPs as well as the 
time before NP entry differed significantly 
between TT1 loaded and Pc4 loaded HSA-NPs 
(Figure S1). As it can be seen in Figure S1A, 
Pc4 homogenously stained the cytoplasm of the 
cells even after 30 minutes of incubation while 
TT1 appears in defined spots indicative for 
endocytic uptake after 4 hours. In order to 
understand the unusual fast entry and cytosolic 
distribution of the Pc4, we tested the particles 
for the presence of free dye with a test 
developed in our lab.44 We incubated red blood 
cells for less than 1 hour with the free Pc4 or 
TT1 dye at 100 ng/µL and 0.2 ng/µL and with 
the respective dye-loaded NPs at the same 
concentrations. While for TT1 no indication of 
free dye was evident, Pc4 NPs gave a strong 
signal (data not shown). Therefore, the 
internalization of the Pc4 from the HSA-NPs is 
indicative for free dye.44 This is supported by 
our data in the stability of Pc4 loaded HSA-NPs 
in presence of FBS at elevated temperature 
where a continuous release of dye from the NPs 
was detectable and the IR data that showed that 
the binding of TT1 to the HSA particles is 
different from that of Pc4 and the interaction of 
Pc4 with the HSA matrix of the NP is much 
weaker. 
TT1-HSA-NPs administration in an 
atherosclerotic mouse model 
The biodistribution of HSA NP loaded with 
TT1 was studied (Figure 3) in a mouse model 
of atherosclerosis in order to measure if the 
HSA accumulate preferentially in the plaques 
or other specific organs. At different time points 
(30 minutes, 3 hours, and 24 hours) after 
intravenous bolus injection of the 1mg/kg (=0.5 
mg NP/mL) dose the mouse was sacrificed and 
selected organs (liver, lungs, spleen, kidneys) 
and atherosclerotic plague in the carotid artery 
were screened for the fluorescence signal from 
TT1 (Figure 7 and S2 in SM).  
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Figure 7. Upper panel: Fluorescence microscopy image from the lungs of a mouse injected with 1 mg/kg TT1-human serum 
albumin (HSA) nanoparticles (NPs) after 30 minutes, 2 hours, and 24 hours. Original magnification 100×. Lower panel: 
Fluorescence microscopy image from the carotid artery of a mouse injected with 1 mg/kg TT1-HSA NP after 30 minutes, 2 
hours, and 24 hours. Original magnification 100×. In the micrograph taken at 30 minutes, the vessel wall is indicated by a 
white line while the lumen of the vessel is indicated by a pink line. The area between the 2 lines presents an atherosclerotic 
plaque obstructing the vessel. The magnification of the image at 30 minutes shows a low fluorescence signal of the TT1 
observable only with maximum gain (inset).  
 
Organs from untreated mice were imaged to 
determine the level of autofluorescence in the 
wavelength range relevant for TT1 detection. 
We focused mainly on organs known to 
accumulate nanoparticles. No fluorescence was 
observed at any of the measured timepoints in 
spleen, liver, and kidneys (Figure S2) as well as 
the organs from untreated mice (data not 
shown). In contrast, in the lungs (Figure 7 upper 
panel) and in the lesions in the carotid arteries 
(Figure 7 lower panel) of nanoparticle-treated 
mice 30 minutes after treatment several 
fluorescent particles (arrows) could be detected 
At later time points no fluorescence signal was 
detected in any of the tested organs except in 
the lungs. The observed low signal in the plague 
as well as the disappearance of the fluorescence 
at later time points indicate a fast clearance of 
the HSA-NPs.
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Figure 8. (A) Flow chart of the pulmonary arterial pressure (PAP), systemic arterial pressure, and HR after bolus injection 
of TT1-human serum albumin nanoparticles (HSA-NP) in pig 2 at different concentrations, saline as negative control and 
Zymosan as positive control. (B) Comparison of PAP in 3 pigs receiving different preparations of HSA-TT1 nanoparticles. 
Pig 1: male, 21 kg, each solution was prepared separately and shipped, max. conc: 1.25 mg NP/mL; Pig 2: male, 21 kg, each 
solution was prepared separately and shipped, max. conentration: 1.25 mg NP/mL; and Pig 3: male, 24 kg, stock solution 15 
mg NP/mL prepared fresh from powder. The diagrams show the PAP in mmHg and the time after injection in mins while the 
arrows indicate the administration of each new drug.  
TT1-HSA-NPs administration in pigs 
A problem frequently limiting the translation 
of nanodrugs in particular liposomal 
formulations into the clinics is a 
hypersensitivity reaction observed in sensitive 
patients, also named complement activation-
related pseudoallergy (CARPA).53.54 The 
symptoms, often a significant increase of PAP 
along with potential changes in HR indicate 
cardiopulmonary distress. Cardiopulmonary 
distress caused by the nanoparticles can be 
critical for CVD patients. Therefore, we 
determined potential cardiopulmonary distress 
induced by the HSA-NPs in in vivo 
experiments in pigs.  
Pigs present an animal model which can 
predict a pseudoallergic response in a fraction 
of human patients. TT1-HSA-NPs were tested 
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in concentrations ranging from 0.1 to 10 mg/kg 
per pig. PAP, SAP, and HR were monitored as 
sensitive parameters to determine a potential 
response to the NP injection (Figure 8A).  
Mild to severe changes in the PAP of the pigs 
were observed in a concentration dependent 
manner (Except in pig 2). In pig 3, the TT1-
HSA-NPs triggered severe PAP changes in a 
concentration dependent manner. The small but 
repeatable reaction indicated the absence of 
self-induced tolerance (tachyphylaxis). The 1.0 
mg/kg evoked mild, >50% increase of PAP that 
remained in the physiological range. However, 
especially for the 1 mg NP/kg we observed the 
strongest dependence on the preparation 
conditions for the initial stock solution (Figure 
8B comparison of pig 1–3). The 10× higher 
dose evoked severe cardiovascular change with 
PAP elevation (Figure 8B pig 3), transient SAP 
decline and HR increase (data not shown). The 
induced change was the same increase in the 
PAP as the positive control zymosan (0.1 
mg/kg) evoked reaction.  
For the other two tested pigs that were 
injected with significantly lower concentration 
of NP solutions we observed only very mild 
reactions (Figure 8B pig 1) to the HSA NP 
suspensions if at all (Figure 8B pig 2). In order 
to understand the reason for the PAP increase 
we tested the plasma level of thromboxane 
(TxB2) and the activation of complement. For 
pig 3 which showed the strongest reaction a 
blood sample was analyzed for the TxB2 level 
(Figure 9). 
 
 
Figure 9. Pulmonary arterial pressure and plasma TxB2 levels for the TT1-human serum albumin doses of 1 and 10 mg/kg 
(stock nanoparticles concentration: 15 mg/mL) weight injected in pig 3. 
PAP and plasma TxB2 increase after bolus 
injection of the TT1-HSA doses in pig 3. 
Together with the increase of PAP, a dose-
dependent TxB2 elevation was observed (2.7 
and 4.9-fold maximal elevation, respectively). 
However, for this high particle concentration, 
we observed an increasing turbidity of the 
solution which can indicate a flocculation that 
may be responsible for rapid PAP rises. The 
individual roles of complement activation, NP 
aggregation and direct activation of pulmonary 
intravascular macrophages (PIM cells)48 in the 
rapid PAP response to HSA NP injection need 
to be explored in the future. The precise 
mechanism for the contradicting 
immunoreactivity of the HSA-NPs or more 
general of nanomedicines is still under debate.55 
After the observation of the adverse effect of 
the higher concentrated HSA-NPs solution we 
reanalyzed the solution by DLS and for the 
release of the TT1 (Table 1). 
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Table 1. Characterization of fresh TT1 HSA-NPs (15 mg/ml) and after 2 weeks of storage in 
physiologic saline at 4°C. 
Sample Name Size [nm] PDI % released dye 
TT1-HSA-NPs 
(immediately after 
preparation) 
290.6±8.5 0.261±0.094 n.d. 
TT1-HSA-NPs (after 2 
weeks storage) 
671.4±36 0.695±0.068 2.65 
HSA = human serum albumin; NP = nanoparticles; PDI = polydispersity index. 
 
The reanalysis of the more concentrated 
nanoparticles by DLS confirmed our 
observation that the NP suspension is not stable 
at this high concentration. For the same NPs at 
a lower concentration of 1 mg/mL NP 
suspension, we observed at 4°C in water no 
change for up to 4 weeks.  
In vitro complement activation 
A significant aspect in the use of 
nanoparticles as a drug delivery system is 
additionally to their low toxicity in general their 
interaction with the immune system. In order to 
determine if TT1 loaded HSA-NPs activate 
complement, they were added to 3 serum 
samples of human blood donors and their 
potential to increase C5a and sC5b-9 levels 
were measured (Figure 10). It is important to 
note that the experiments were carried out with 
separate serum samples and not with pooled 
blood. 
 
 
 
Figure 10. Effect of TT1-human serum albumin nanoparticles on human complement in vitro. Complement activation markers 
(A) C5a, (B) sC5b-9. Blank (phosphate buffer solution) and positive control (1 mg/mL Zymosan) were tested for one serum 
was shown. Zymosan-induced rises of serum C5a and sC5b-9 levels were 170 ng/mL serum and 36722 ng/mL serum (not 
shown), respectively. Each experiment was repeated with 3 individual sera. Activation pattern was similar in other tested sera. 
 
Results show that TT1-HSA-NPs up to 2 
mg/mL concentration are poor activators of the 
terminal pathway of the human complement 
system. Since Hamblin (one of the pioneers in 
the field of PDT of macrophage targeting Pc) 
suggested its use for vulnerable plaques in 
cardiovascular disease56,57 and the first patent in 
199423, research aiming to localize, image, and 
treat vulnerable plaques in a non- or minimally 
invasive way was intensified. The factors 
defining plaques as vulnerable to rupture have 
high macrophage infiltration, a thin fibrotic cap 
and extended necrotic core.58,59 The review of 
Hellings et al.59 summarizes that the main 
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problem of a contrast agent free detection is a 
limitation of the sensitivity and/or specificity as 
only the calcification (i.e., stable plaques) can 
be detected with 100% in computed 
tomography and hemorrhage (ruptured plaque) 
in MRI. The most promising technique is 
optical coherence tomography with satisfying 
confidence in both sensitivity and specificity 
and a high spatial resolution, which is important 
for early detection of plaques and macrophages. 
However, these techniques allow only 
visualization without the possibility of 
treatment. Hence, simultaneous detection and 
treatment of vulnerable plaques and especially 
the infiltrating macrophages is a still unmet 
medical need.  
In the present study, we described the 
biological profile of glutaraldehyde cross-
linked albumin NPs loaded with the novel NIR 
photosensitizer, TT1. These NPs were tested 
for light-induced toxicity in macrophages as 
attempted target cells for CVD PDT, 
immunoreactivity measured in vitro by 
complement activation and in vivo by 
cardiovascular distress syndrome in pigs as 
well as their accumulation in arteriosclerotic 
plaque in vivo in a mouse model.  
Several other works reported about the use of 
Pc for the treatment as a cancer drug or as a 
treatment for arteriosclerosis. Davanzo et al.60 
published a study in which they investigate the 
role of the light source and dose on the 
efficiency of AlPc delivered by albumin NPs to 
induce cell death in glioma cells in vitro. A 
direct comparison with our results is difficult as 
the highest light dose used by them with the 
LED is significantly lower than in our 
experiments and the loading efficacy of the 
photosensitizer to the albumin NPs is missing. 
However, they found that the most efficient 
light source is the continuous wave laser 
illumination at low non-toxic light doses. In our 
case even at the high light dose, which is 2.6-
times higher, we did not observe any 
phototoxicity on the cells without the 
photosensitizer. Even the targeted delivery of 
albumin-conjugated Pc to tumor-infiltrating 
macrophages was reported in previous 
studies.61 Brasseur et al.61 reported the 
selective uptake of AlPc covalently bound to 
maleylated bovine serum albumin BSA 
molecules by tumor-infiltrating macrophages in 
comparison to non-macrophage cell lines. They 
required the conjugation of the Pc molecules 
because in order to have an increased uptake 
and a shift from membrane damage induced 
necrosis to apoptosis.  
The fluorescence images of the RAW cells 
treated with our NPs showed a high amount of 
photosensitizer located within the cell that will 
induce a preferential intracellular cell damage 
leading to apoptosis even without a targeting 
molecule. Our observation that the albumin 
NPs without light activation are well-tolerated 
by the cells is in good agreement with the non-
toxicity of the BSA conjugates found by 
Brasseur and co-workers.61 In a recently 
published work Molina et al.62 compared the 
delivery of glutaraldehyde cross-linked HSA-
NPs for the delivery of photosensitizer Ce6 to 
tumor cells with NPs cross-linked with a redox-
sensitive cross-linker, which will break down in 
presence of glutathione in the cell cytosol. 
Here, differently from our approach, the 
photosensitizer was covalently bound to the 
albumin NPs. In summary, they observed a 
much lower cell-killing efficacy of 
glutaraldehyde cross-linked NPs that are not 
releasing the dye as compared to the redox-
sensitive NPs.62 This is in good agreement with 
our observation that the quantum yield of the 
NP bound dye is usually lower than that of the 
free Pc in DMSO. One possible explanation is 
that the produced singlet oxygen is partially 
degrading the albumin matrix rather than being 
released.  
The stark contrast between our results in 
human serum, where no complement activation 
took place, and the pig experiments, which 
showed a significant increase in thromboxane 
and a hyperreaction in terms of increase in 
pulmonary arterial pressure needs an 
explanation.  
The fast accumulation of the lungs we 
observed in the mice can explain the 
contradictory results about the absence of 
complement activation in human serum and the 
hyperreactivity of the pigs. Earlier experiments 
with albumin microparticles in pigs showed 
that hyperreactivity in pigs can be due to the 
accumulation of the material in PIMs and may 
cause a significant increase in plasma TxB2 
levels63,64 which is in accordance to our own 
observations. The studies reported also that the 
immune response is strongly species-dependent 
and is rarely observed in humans.  
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Summary 
Summarizing the results, we have found that TT1 loaded HSA-NPs localize in the endosomal vesicles 
rather than in the cell membrane, and when illuminate they show a good cell-killing activity in the low 
µg/mL range with low immunoreactivity in vivo and complement activation potential in vitro. In an 
atherosclerotic mouse model, loaded nanoparticles localized in the plaques 30 minutes after injection 
in the tail vein. The localization of TT1-loaded NPs in the plaques allows the visualization of 
atherosclerotic areas in vessels and offers high-singlet oxygen production along with NIR light-induced 
macrophage killing, fulfilling some of the requirements for a candidate as a contrast agent and PDT 
treatment for CVD. 
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Supplementary information 
 
Table S1. Influence of solvent and experimental conditions at fast addition on the size of HSA 
nanoparticles 
Solvent 1 Solvent 2 ratio Volume [ml] Hydrodynamic 
diameter  
PDI (one peak) 
Ethanol  -  2 249.9± 13.61 0.263± 0.051 
Ethanol  Water  7:1 2 289.5 ±7.2 0.219± 0.09 
Ethanol  Methanol  2.4:5.6 2 269.2 ±4.25 0.339± 0.015 
Acetone  -  1) 1  
2) 2  
316.5± 5.15 
218.4± 8.12 
0.18± 0.031 
0.375± 0.045 
Acetone  Water  7:1 1) 1  
2) 2  
278.6 ±36.24 
172.9± 6.14 
0.508± 0.166 
0.498± 0.087 
Acetone  Water  6:2 2 127.6± 3.39 0.165± 0.019 
 
Table S2. HSA nanoparticle parameters versus photosensitizer concentration for Pc4-HSA and TT1-
HSA NPs  
Sample  Added Dye 
Conc [mM] 
Diameter 
[nm] 
PDI  Zeta potential 
[mV] 
Encapsulation 
efficiency [%] 
Singlet O2 
Quantum 
Pc4-HSA 0.70 248.3± 5.3 0.2±0.02 -13.3±0.5 47.7 0.0142 
Pc4-HSA 1.04 266.4± 1.2 0.21±0.05 -22.5±1.3 60.2 0.063 
Pc4-HSA 1.40 284.4± 1.4 0.27±0.04 -25.7±0.5 69.2 0.099 
TT1-HSA 0.63 203.6± 7.1 0.15±0.06 -28.8±0.1 40.5 0.016 
TT1-HSA 0.95 243.5± 7.1 0.25±0.05 -28.5±1.1 76.3 0.0363 
TT1-HSA 1.27 278.4± 9.6 0.27±0.07 -31.3±1.15 78.2 0.0499 
 
 
Table S3: Stability of Pc4 loaded HSA NPs for 6 weeks kept in 4ºC determined by the 
hydrodynamic diameter and the polydispersity index (PDI) measured in DLS and Pc4 release 
measured by the fluorescence 
TIME IN 
WEEKS 
Z-AVG 
HYDROYNAMIC 
DIAMETER (nm) 
PDI % Pc4 RELEASE 
1 248.3 ± 5.3 0.197 ± 0.02 no release 
2 269.3 ± 4.3 0.165 ± 0.07 no release 
3 268.3 ± 5.6 0.292 ± 0.01 no release 
4 221.5 ± 2.6 0.201 ± 0.02 0.8 
6 193.6 ± 2.1 0.266 ± 0.01 4.45 
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Table S4: Stability of TT1 loaded HSA NPs for 6 weeks kept in 4ºC determined by the 
hydrodynamic diameter and the polydispersity index (PDI) measured in DLS and Pc4 release 
measured by fluorescence 
TIME IN 
WEEKS 
Z-AVG HYDROYNAMIC 
DIAMETER (nm) 
PDI % TT1 RELEASE 
1 203.3 ± 7.14 0.147 ± 0.056 no release 
2 322.9 ± 20.99 0.204 ± 0.041 no release 
3 227.9 ± 19.79 0.298 ± 0.124 no release 
4 367.0 ± 15.30 0.237 ± 0.047 9.03 
6 313.4 ± 28.77 0.439 ± 0.292 36.13 
 
 
 
 
 
Figure S1. Cellular uptake and localisation study in RAW264.7 macrophage cells. Images were acquired at 30 mins, 2 h, 4 h 
and 24 h after incubation with (A) Pc4-HSA NPs (0.2 mg/mL) or (B) TT1-HSA NPs (0.2 mg/mL). 
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Figure S2. Nanoparticle distribution in different organs such as liver, spleen and kidney at different timepoints 30 mins, 3 h 
and 24h after injection in an arteriosclerotic mous 
